Syngene Expands U.S. Presence with Biologics Facility Acquisition
Deal News | Mar 10, 2025 | PR Newswire Cision Syngene International
Syngene International Limited, a prominent contract research, development, and manufacturing organization (CRDMO), has acquired its first biologics manufacturing site in the United States. The facility, located in Baltimore and previously owned by Emergent Manufacturing Operations Baltimore, LLC, is expected to enhance Syngene's global capabilities, especially in producing monoclonal antibodies (mAbs) for human and animal health markets. With this acquisition, Syngene's total bioreactor capacity will expand to 50,000 liters. The strategic move underscores Syngene's commitment to the U.S. market, creating jobs and strengthening healthcare infrastructure. Peter Bains, CEO Designate, emphasized the enhanced service flexibility this acquisition provides to global clients. The investment, worth an estimated $50 million, including $36.5 million for the acquisition price, will be funded internally. The deal, expected to close in March 2025, aligns with both India's and the U.S.' aspirations for stronger economic collaboration.
Sectors
- Biotechnology
- Pharmaceuticals
- Healthcare
Geography
- United States – The location of the newly acquired biologics facility, marking Syngene's strategic expansion into the U.S. market.
- India – The headquarters of Syngene International Limited and integral to the company's global operations and collaborations.
Industry
- Biotechnology – The acquisition involves a biologics manufacturing facility, pivotal for advancing drug development and innovation in pharmaceuticals.
- Pharmaceuticals – The facility supports pharmaceutical manufacturing and aligns with the strategic growth in the biologics drug market.
- Healthcare – Enhancing manufacturing capabilities contributes to healthcare infrastructure and drug innovation.
Financials
- US$50 million – The total investment estimated for the U.S. biologics facility acquisition and its operational setup.
- US$36.5 million – The acquisition cost of the Baltimore facility from Emergent Manufacturing Operations.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Syngene International Limited | Acquiring Company | Company | A global contract research, development, and manufacturing organization (CRDMO) expanding into the U.S. biologics market. |
| Emergent Manufacturing Operations Baltimore, LLC | Selling Company | Company | A subsidiary of Emergent BioSolutions Inc. from which Syngene acquired the Baltimore biologics facility. |
| Peter Bains | CEO Designate | Person | Leader at Syngene highlighting the strategic benefits and objectives of the acquisition. |
| Alex Del Priore | Senior Vice President – Development & Manufacturing Services | Person | Executive at Syngene citing the milestone significance of the U.S. facility acquisition. |
| Deepak Jain | CFO | Person | Provided financial insights on the acquisition's impact and funding strategy. |